These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37008395)

  • 1. Relationship Between Macular Thickness and Visual Acuity in the Treatment of Diabetic Macular Edema With Anti-VEGF Therapy: Systematic Review.
    Wang P; Hu Z; Hou M; Norman PA; Chin EK; Almeida DR
    J Vitreoretin Dis; 2023; 7(1):57-64. PubMed ID: 37008395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the relationship between visual acuity and central retinal (macular) thickness after interventions for macular oedema in diabetics: a review.
    Bong A; Doughty MJ; Button NF; Mansfield DC
    Clin Exp Optom; 2016 Nov; 99(6):491-497. PubMed ID: 27320640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.
    Laiginhas R; Silva MI; Rosas V; Penas S; Fernandes VA; Rocha-Sousa A; Carneiro Â; Falcão-Reis F; Falcão MS
    Graefes Arch Clin Exp Ophthalmol; 2018 Jan; 256(1):83-89. PubMed ID: 29082448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.
    Mehta H; Hennings C; Gillies MC; Nguyen V; Campain A; Fraser-Bell S
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011599. PubMed ID: 29669176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combined pharmacosurgery as treatment for diabetic macular edema: core pars plana vitrectomy and intravitreal injection of bevacizumab and triamcinolone].
    Naser H; Koss MJ; Singh P; Koch F
    Klin Monbl Augenheilkd; 2011 Oct; 228(10):910-4. PubMed ID: 21997827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-vascular endothelial growth factor therapy in diabetic macular edema: real-life outcomes from a multicenter study in Turkey over 36 months.
    Durukan AH; Unlu N; Onen M; Alp MN; Yeşiltaş YS; Kalayci D; Acar MA; Sekeroglu MA; Citirik M; Altintas AGK; Hazirolan D; Kucukevcilioglu M; Ozdal PC; Toklu Y; Bicer T; Ugurlu N; Budakoglu O; Yazar Z; Ucgun NI; Serdar K; Doguizi S; Erol YO; Atilgan CU; Yorgun MA; Soba DO; Berker N; Baskan C; Yilmaz ES
    Int Ophthalmol; 2022 Dec; 42(12):3777-3787. PubMed ID: 35829865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial.
    Jampol LM; Glassman AR; Bressler NM; Wells JA; Ayala AR;
    JAMA Ophthalmol; 2016 Dec; 134(12):. PubMed ID: 27711918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in choroidal thickness after anti-vascular endothelial growth factor treatment of diabetic macular edema, real-life data, 2-year results.
    Savur F; Kaldırım H; Atalay K; Korkmaz Ş
    Cutan Ocul Toxicol; 2021 Dec; 40(4):326-331. PubMed ID: 34275395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of macular hydration in the evaluation of the effect of intravitreal triamcinolone on visual acuity in eyes with diabetic macular edema.
    Sonmez K; Tezel TH; Kaplan HJ
    Int Ophthalmol; 2013 Feb; 33(1):15-25. PubMed ID: 22890369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to Initial Anti-Vascular Endothelial Growth Factor for Diabetic Macular Edema Is Significantly Correlated with Response to Third Consecutive Monthly Injection.
    Maeda S; Sugimoto M; Tenma Y; Tsukitome H; Kato K; Chujo S; Matsui Y; Matsubara H; Kondo M
    J Clin Med; 2022 Oct; 11(21):. PubMed ID: 36362644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
    Spooner K; Fraser-Bell S; Hong T; Chang A
    Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema.
    Avitabile T; Longo A; Reibaldi A
    Am J Ophthalmol; 2005 Oct; 140(4):695-702. PubMed ID: 16226521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
    Shalchi Z; Mahroo O; Bunce C; Mitry D
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD009510. PubMed ID: 32633861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of Vitreo-Macular interface abnormalities on the response to Anti-VEGF therapy for centre involving diabetic macular oedema.
    Maguire M; Laidlaw D; Davies N; Hammond C
    Graefes Arch Clin Exp Ophthalmol; 2024 May; ():. PubMed ID: 38771336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of fundus autofluorescence with spectral-domain optical coherence tomography and vision in diabetic macular edema.
    Chung H; Park B; Shin HJ; Kim HC
    Ophthalmology; 2012 May; 119(5):1056-65. PubMed ID: 22342014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab: A Post Hoc Analysis of the Protocol T Randomized Clinical Trial.
    Bressler NM; Odia I; Maguire M; Glassman AR; Jampol LM; MacCumber MW; Shah C; Rosberger D; Sun JK;
    JAMA Ophthalmol; 2019 Sep; 137(9):977-985. PubMed ID: 31246237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study).
    Glassman AR; Wells JA; Josic K; Maguire MG; Antoszyk AN; Baker C; Beaulieu WT; Elman MJ; Jampol LM; Sun JK
    Ophthalmology; 2020 Sep; 127(9):1201-1210. PubMed ID: 32402554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of Eyes Lost to Follow-up with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Anti-Vascular Endothelial Growth Factor.
    Soares RR; Mellen P; Garrigan H; Obeid A; Wibbelsman TD; Borkar D; Ho AC; Hsu J
    Ophthalmol Retina; 2020 Feb; 4(2):134-140. PubMed ID: 31540854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months.
    Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
    Retina; 2010; 30(7):1002-11. PubMed ID: 20616679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of switching therapy to aflibercept for patients with persistent diabetic macular edema: a systematic review and meta-analysis.
    Liu Y; Cheng J; Gao Y; Qin L; Min X; Zhang M
    Ann Transl Med; 2020 Mar; 8(6):382. PubMed ID: 32355826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.